Paradigm Biopharmaceuticals Ltd Sustainability Reports

Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company engaged in researching and developing therapeutic products for human use. It focuses on repurposing historical drugs, primarily injectable pentosan polysulfate sodium (iPPS), to treat musculoskeletal disorders and inflammatory diseases such as osteoarthritis.

Sector: Manufacturing

Country: Australia

Exchange: Australian Securities Exchange

LEI: 984500AED3956615CA10

FIGI: BBG009QNWX94

12 reports from 2015 to 2026

• Paradigm Biopharmaceuticals Ltd 2026 Preliminary Final Report to the Australian Stock Exchange
• Paradigm Biopharmaceuticals Ltd 2025 Annual Report
• Paradigm Biopharmaceuticals Ltd 2024 Annual Report
• Paradigm Biopharmaceuticals Ltd 2023 Annual Report
• Paradigm Biopharmaceuticals Ltd 2022 Annual Report